210 related articles for article (PubMed ID: 35617303)
1. Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5' splice site: Generation of etoposide resistance in human leukemia K562 cells.
Hernandez VA; Carvajal-Moreno J; Wang X; Pietrzak M; Yalowich JC; Elton TS
PLoS One; 2022; 17(5):e0265794. PubMed ID: 35617303
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 Genome Editing of the Human Topoisomerase II
Hernandez VA; Carvajal-Moreno J; Papa JL; Shkolnikov N; Li J; Ozer HG; Yalowich JC; Elton TS
Mol Pharmacol; 2021 Mar; 99(3):226-241. PubMed ID: 33446509
[TBL] [Abstract][Full Text] [Related]
3. Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform.
Kanagasabai R; Serdar L; Karmahapatra S; Kientz CA; Ellis J; Ritke MK; Elton TS; Yalowich JC
J Pharmacol Exp Ther; 2017 Jan; 360(1):152-163. PubMed ID: 27974648
[TBL] [Abstract][Full Text] [Related]
4.
Wang X; Carvajal-Moreno J; Zhao X; Li J; Hernandez VA; Yalowich JC; Elton TS
Mol Pharmacol; 2024 May; ():. PubMed ID: 38719474
[TBL] [Abstract][Full Text] [Related]
5. Use of CRISPR/Cas9 with Homology-Directed Repair to Gene-Edit Topoisomerase II
Carvajal-Moreno J; Wang X; Hernandez VA; Mondal M; Zhao X; Yalowich JC; Elton TS
J Pharmacol Exp Ther; 2024 Apr; 389(2):186-196. PubMed ID: 38508753
[TBL] [Abstract][Full Text] [Related]
6. The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase II
Kanagasabai R; Karmahapatra S; Kientz CA; Yu Y; Hernandez VA; Kania EE; Yalowich JC; Elton TS
Mol Pharmacol; 2018 May; 93(5):515-525. PubMed ID: 29514855
[TBL] [Abstract][Full Text] [Related]
7. Intronic Polyadenylation in Acquired Cancer Drug Resistance Circumvented by Utilizing CRISPR/Cas9 with Homology-Directed Repair: The Tale of Human DNA Topoisomerase IIα.
Elton TS; Hernandez VA; Carvajal-Moreno J; Wang X; Ipinmoroti D; Yalowich JC
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804920
[TBL] [Abstract][Full Text] [Related]
8. hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II
Kania EE; Carvajal-Moreno J; Hernandez VA; English A; Papa JL; Shkolnikov N; Ozer HG; Yilmaz AS; Yalowich JC; Elton TS
Mol Pharmacol; 2020 Mar; 97(3):159-170. PubMed ID: 31836624
[TBL] [Abstract][Full Text] [Related]
9. Effects of hsa-miR-9-3p and hsa-miR-9-5p on Topoisomerase II
Carvajal-Moreno J; Hernandez VA; Wang X; Li J; Yalowich JC; Elton TS
J Pharmacol Exp Ther; 2023 Feb; 384(2):265-276. PubMed ID: 36410793
[TBL] [Abstract][Full Text] [Related]
10. Effects of DNA topoisomerase IIα splice variants on acquired drug resistance.
Elton TS; Ozer HG; Yalowich JC
Cancer Drug Resist; 2020; 3(2):161-170. PubMed ID: 32566920
[TBL] [Abstract][Full Text] [Related]
11. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
12. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.
Ritke MK; Yalowich JC
Biochem Pharmacol; 1993 Dec; 46(11):2007-20. PubMed ID: 8267650
[TBL] [Abstract][Full Text] [Related]
13. Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness.
Chen CF; He X; Arslan AD; Mo YY; Reinhold WC; Pommier Y; Beck WT
Mol Pharmacol; 2011 Apr; 79(4):735-41. PubMed ID: 21252292
[TBL] [Abstract][Full Text] [Related]
14. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Wessel I; Jensen PB; Falck J; Mirski SE; Cole SP; Sehested M
Cancer Res; 1997 Oct; 57(20):4451-4. PubMed ID: 9377550
[TBL] [Abstract][Full Text] [Related]
15. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
[TBL] [Abstract][Full Text] [Related]
16. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
17. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
[TBL] [Abstract][Full Text] [Related]
18. FAM122A maintains DNA stability possibly through the regulation of topoisomerase IIα expression.
Wang YQ; Yang YS; Chen J; Liu MH; Chen GQ; Huang Y
Exp Cell Res; 2020 Nov; 396(1):112242. PubMed ID: 32866497
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.
Asano T; Nakamura K; Fujii H; Horichi N; Ohmori T; Hasegawa K; Isoe T; Adachi M; Otake N; Fukunaga Y
Br J Cancer; 2005 Apr; 92(8):1486-92. PubMed ID: 15798770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
